"Naphthalimides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.
| Descriptor ID |
D053644
|
| MeSH Number(s) |
D02.478.480 D03.383.621.808.612 D03.633.100.531.460 D04.615.638.596
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naphthalimides".
Below are MeSH descriptors whose meaning is more specific than "Naphthalimides".
This graph shows the total number of publications written about "Naphthalimides" by people in this website by year, and whether "Naphthalimides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naphthalimides" by people in Profiles.
-
Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD. Sci Rep. 2017 09 18; 7(1):11793.
-
Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4. PLoS One. 2013; 8(6):e65404.
-
Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008 May; 7(5):377-88.
-
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem. 2005 Aug 12; 280(32):29060-6.
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
-
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. Invest New Drugs. 1995; 13(3):249-52.
-
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 1992 Aug; 46(2):230-2.
-
Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6.
-
In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85.